Ultimate Guide to Oncosil Pancreatic Care

Introduction

Pancreatic cancer is one of the most aggressive and complex malignancies in modern medicine. Among the latest advancements in its management is OncoSil, an innovative internal radiotherapy technology designed to deliver targeted treatment directly into the tumor. At Liv Hospital, this approach is integrated into a multidisciplinary framework that combines surgical, oncological, and interventional expertise to improve patient outcomes.

OncoSil involves injecting radioactive phosphorus-32 microspheres into the tumor using endoscopic or surgical techniques. This targeted radiation minimizes exposure to surrounding healthy tissues while maximizing therapeutic impact on cancer cells. The combination of OncoSil and systemic chemotherapy is transforming the way pancreatic head cancers are treated, providing hope for patients who were previously considered inoperable.

Understanding Pancreatic Head Cancer

Pancreatic head cancer originates in the portion of the pancreas that lies closest to the small intestine. Because of its location, tumors in this area can cause early symptoms such as jaundice, abdominal pain, or digestive problems. Unfortunately, these symptoms often appear after the disease has progressed, which makes early diagnosis challenging.

Pancreatic head cancers are commonly adenocarcinomas that arise from the pancreatic ducts. They often spread to nearby lymph nodes or major blood vessels, which limits surgical options. For this reason, many patients are diagnosed at stages where surgery alone cannot provide a cure. Combining advanced therapies like OncoSil with chemotherapy and supportive care can improve survival and quality of life.

The Role of OncoSil in Pancreatic Cancer Treatment

OncoSil is a medical device containing microscopic spheres that emit beta radiation from phosphorus-32. These microspheres are implanted directly into the tumor under imaging guidance, typically through endoscopic ultrasound. The radiation works locally, destroying cancer cells from within without significant harm to surrounding structures such as the duodenum, stomach, or major blood vessels.

This localized radiation therapy is especially beneficial for patients with borderline resectable or unresectable pancreatic head cancer. It can reduce tumor volume, lower metabolic activity, and increase the chances of surgical resection later on. The treatment is performed within a controlled hospital environment by specialized interventional gastroenterologists or surgeons.

Liv Hospital’s multidisciplinary cancer center provides the infrastructure and expertise necessary to carry out this procedure safely and effectively.

How OncoSil Works

The OncoSil system is based on the principle of internal radiotherapy, also known as brachytherapy. Instead of directing radiation beams from outside the body, OncoSil places the radioactive material directly inside the tumor.

Phosphorus-32, a beta-emitting isotope, has a half-life of 14.27 days, meaning its radioactivity decreases by half every two weeks. Within approximately 81 days, more than 98 percent of its radiation energy is absorbed by the surrounding tumor tissue. This ensures long-term effectiveness with minimal systemic exposure.

Once injected, the microspheres remain inside the tumor permanently. Their radiation gradually destroys cancer cells and shrinks the tumor. The treatment can be combined with chemotherapy regimens such as FOLFIRINOX or nab-paclitaxel plus gemcitabine, allowing both local and systemic control of the disease.

Multidisciplinary Treatment at Liv Hospital

Liv Hospital’s approach to pancreatic head cancer is built on collaboration among multiple medical specialties. Every patient case is reviewed by a dedicated tumor board that includes experts from surgery, medical oncology, nuclear medicine, interventional radiology, and gastroenterology. This ensures that treatment decisions are made based on the most accurate information and latest medical standards.

The multidisciplinary process includes:

1. Patient Evaluation: Clinical assessment, imaging, and laboratory review.
2. Treatment Planning: Determination of tumor resectability and therapy sequence.
3. OncoSil Application: Endoscopic or surgical injection of phosphorus-32 microspheres.
4. Systemic Chemotherapy: Administration of established regimens to complement local therapy.
5. Reevaluation: Imaging studies such as PET/CT and MRI performed after at least three months.
6. Surgical Consideration: Patients with a favorable response may proceed to potentially curative surgery.

This coordinated strategy enhances communication among specialists and ensures individualized patient care.

Patient Selection and Eligibility

OncoSil is intended for adult patients with pancreatic head adenocarcinoma who meet specific clinical criteria. Candidates typically have locally advanced or borderline resectable tumors that cannot be safely removed at diagnosis. They should also be able to tolerate standard chemotherapy.

Eligibility requirements include:

• Age 18 years or older
• Borderline resectable or unresectable pancreatic head cancer
• Karnofsky Performance Score of 70 or higher
• Good organ function to handle chemotherapy
• No pregnancy or breastfeeding during treatment
• Suitability for palliative treatment if needed

These criteria help identify patients most likely to benefit from the therapy.

When OncoSil Is Not Suitable

OncoSil is not appropriate for all patients. It is contraindicated in the following cases:

• Distant metastasis to the liver, lungs, or peritoneum
• Tumors affecting multiple regions of the pancreas
• Lack of endoscopic access to the tumor site
• Severe comorbid conditions that increase procedural risk
• History of another active cancer within the last five years
• Pregnancy or lactation

The goal is to ensure safety and maximize the benefits of treatment for suitable candidates.

Advantages of OncoSil Therapy

OncoSil provides several clinical advantages compared to conventional radiotherapy:

• Delivers radiation directly to the tumor site
• Minimizes damage to healthy tissues
• May increase chances of surgical resection
• Can be safely combined with chemotherapy
• Offers potential survival benefit even in non-surgical patients
• Reduces pain and pressure caused by tumor growth
• Allows faster recovery and shorter hospital stays

Liv Hospital integrates this technology within a high-standard medical environment, ensuring that patients receive the most advanced and personalized care possible.

Treatment Procedure and Recovery

The OncoSil procedure is performed under general anesthesia in a sterile endoscopy or surgical suite. Using endoscopic ultrasound, the specialist visualizes the tumor and delivers the phosphorus-32 microspheres through a fine needle directly into the cancerous tissue.

The entire procedure typically takes less than one hour. Most patients can return home within one or two days, depending on their overall condition. Common side effects may include mild abdominal pain, nausea, fatigue, or transient digestive discomfort. These symptoms are short-lived and manageable with medication.

After treatment, patients continue systemic chemotherapy and undergo regular imaging to monitor tumor response. At Liv Hospital, follow-up visits are coordinated through a patient-centered monitoring system that ensures timely management of side effects and therapy adjustments.

Clinical Outcomes and Research

Studies have demonstrated that OncoSil can significantly reduce tumor volume and improve local control. When used alongside chemotherapy, it enhances progression-free survival and may allow some previously unresectable tumors to become operable.

Clinical trials are ongoing to evaluate the long-term impact of OncoSil on survival and quality of life. Early data suggest that combining local radiotherapy with systemic therapy improves both local disease management and patient comfort.

Liv Hospital participates in evidence-based research and training programs to refine these treatment methods further. The institution’s academic collaborations and advanced imaging technologies support continuous innovation in pancreatic cancer therapy.

Liv Hospital’s Center Highlights

Liv Hospital’s pancreatic cancer program is distinguished by:

• Expert surgeons with experience in hepatobiliary and pancreatic procedures
• Access to interventional radiology and nuclear medicine
• Dedicated tumor board for individualized decision-making
• Modern operating rooms and endoscopic suites equipped with advanced imaging
• Comprehensive patient care and follow-up programs
• Collaboration with Liv Hospital Academy for research and medical education

This integrated infrastructure ensures that patients receive advanced therapies like OncoSil in a safe, research-oriented, and patient-centered environment.

Quality of Life After OncoSil

Patients who receive OncoSil treatment often report improvement in symptoms such as abdominal pain, fatigue, and appetite loss. Because the radiation is targeted directly at the tumor, it reduces collateral damage to healthy tissues and preserves pancreatic function.

At Liv Hospital, supportive care plays a key role in the overall treatment journey. Nutritionists, psychologists, and pain management specialists work alongside oncologists to ensure each patient maintains quality of life throughout therapy.

This comprehensive approach addresses both the physical and emotional challenges of living with pancreatic cancer.

Conclusion

OncoSil is redefining the treatment landscape for pancreatic head cancer by offering targeted internal radiotherapy with minimal side effects. Through a multidisciplinary approach, Liv Hospital combines this advanced technology with world-class surgical and oncological expertise to improve patient survival and quality of life.

For individuals with borderline or unresectable pancreatic tumors, OncoSil provides new hope and a pathway toward better control, longer survival, and more effective personalized care.

Liv Hospital continues to lead in innovation, research, and compassionate treatment, making it a reference center for advanced oncological therapies.

* Liv Hospital Editorial Board has contributed to the publication of this content .
* Contents of this page is for informational purposes only. Please consult your doctor for diagnosis and treatment. The content of this page does not include information on medicinal health care at Liv Hospital .

For more information about our academic and training initiatives, visit Liv Hospital Academy

Frequently Asked Questions